Promising Penny Stocks To Watch In September 2026

Over the past 7 days, the U.S. market has dropped by 1.5%, yet it has risen by 13% over the last year, with earnings forecasted to grow annually by 18%. In such a fluctuating market, investors often seek stocks that combine affordability and growth potential, making penny stocks an intriguing option despite their somewhat outdated label. These smaller or newer companies can offer unique opportunities for growth when backed by strong financials; we'll explore several that stand out for their potential in today's economic landscape.

Below we spotlight a couple of our favorites from our exclusive screener.

Accuray (ARAY)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for tumor treatment globally, with a market cap of $25.69 million.

Operations: The company's revenue is derived from its Oncology Systems Group, which generated $401.95 million.

Market Cap: $25.69M

Accuray's recent strategic partnerships with Samsung NeuroLogica and RaySearch are aimed at enhancing its CyberKnife System and expanding online adaptive radiation therapy capabilities. Despite these collaborations, Accuray faces financial challenges, including a significant net loss of US$49.19 million for the year ending June 2026, alongside a high debt-to-equity ratio of 257.2%. The company's cash runway remains stable for over a year at current free cash flow levels. However, volatility persists in its share price and weekly returns. Recent leadership changes aim to improve operational efficiency and profitability amidst ongoing financial pressures.

• Dive into the specifics of Accuray here with our thorough balance sheet health report.
• Understand Accuray's track record by examining our performance history report.

Filana Therapeutics (FLNA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Filana Therapeutics, Inc. is a clinical stage biotechnology company focused on developing drugs for neurodegenerative diseases, with a market cap of $36.14 million.

Operations: Filana Therapeutics, Inc. has not reported any revenue segments.

Market Cap: $36.14M

Filana Therapeutics, Inc. is navigating the complexities of being a pre-revenue biotech firm with a market cap of US$36.14 million. The company recently received FDA clearance to proceed with a Phase 2a study for simufilam in TSC-related epilepsy, marking a significant step forward in its clinical pipeline. Despite this progress, Filana faces challenges such as non-compliance with Nasdaq's minimum bid price requirement and recent exclusion from the S&P Global BMI Index. While debt-free and possessing sufficient short-term assets to cover liabilities, it remains unprofitable with declining earnings forecasts over the next three years.

• Unlock comprehensive insights into our analysis of Filana Therapeutics stock in this financial health report.
• Examine Filana Therapeutics' earnings growth report to understand how analysts expect it to perform.

Baozun (BZUN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Baozun Inc. provides comprehensive e-commerce solutions in China and has a market cap of approximately $170.93 million.

Operations: The company's revenue is primarily derived from its E-Commerce segment, which generated CN¥8.55 billion, and its Brand Management segment, contributing CN¥2.08 billion.

Market Cap: $170.93M

Baozun Inc. is navigating the penny stock landscape with a market cap of approximately US$170.93 million, driven by its E-Commerce and Brand Management segments generating CN¥8.55 billion and CN¥2.08 billion respectively. Recent earnings show revenue growth to CN¥2,742.97 million for Q2 2026, with net income improving from a loss to CN¥17.02 million year-over-year, highlighting reduced losses over five years despite being unprofitable overall. The company maintains strong financial health with short-term assets exceeding liabilities and a positive cash flow runway for over three years, though it trades significantly below estimated fair value amid industry challenges.

• Navigate through the intricacies of Baozun with our comprehensive balance sheet health report here.
• Gain insights into Baozun's future direction by reviewing our growth report.

Taking Advantage

• Gain an insight into the universe of 328 US Penny Stocks by clicking here.
• Interested In Other Possibilities? Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com